Evidence mapping of clinical research on prevention and treatment of hyperlipidemia with Chinese patent medicines_Chinese Journal of Evidence-Based Medicine

Authors：

YU Pengzhen ^1,2 , YAN Jingjing ^1,2 , LIANG Beibei ^1,2 , LI Jia ^1,2 ,  LI Bin ^1,3

1. Heart Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, P. R. China;
2. The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450000, P. R. China;
3. Henan Evidence-based Chinese Medicine Center, Zhengzhou 450000, P. R. China;

Corresponding?author：

LI Bin, Email: libinnvhai@163.com

Keywords：

Traditional Chinese medicine; Hyperlipidemia; Clinical research; Evidence map; Methodology

DOI：

10.7507/1672-2531.202310005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To use the evidence map system to search and sort out the clinical research on the prevention and treatment of hyperlipidemia with proprietary Chinese medicine, and to understand the distribution of evidence in this field. Methods The literature on the treatment of hyperlipidemia with proprietary Chinese medicines was retrieved from CNKI, WanFang Data, VIP, SinoMed, PubMed, Cochrane Library, Embase and Web of Science databases from inception to December 2022. The distribution characteristics of evidence were analyzed and presented by means of text and graph. Results A total of 865 articles were included and 79 kinds of proprietary Chinese medicines were obtained. The Xuezhikang tablets or capsules were the most frequently used. In recent years, the number of published articles showed a downward trend, and the literature quality was generally low. Most of the research intervention programs only used Chinese patent medicine, and the sample size of a single study was mostly 60-100 patients, and the study course was 4-8 weeks. Clinical studies did not highlight the characteristics of traditional Chinese medicine, and only 12.7% of the studies limited the syndrome type of traditional Chinese medicine in the study population. In terms of the selection of outcome indicators, more attention was paid to blood lipid levels and safety indicators, while less attention was paid to indicators such as traditional Chinese medicine syndrome scores. Conclusion The results show that Chinese patent medicine has certain advantages in the prevention and treatment of hyperlipidemia, but there are some deficiencies in the reports of methodology and clinical characteristics, and the overall quality of the research is low.

Citation： YU Pengzhen, YAN Jingjing, LIANG Beibei, LI Jia, LI Bin. Evidence mapping of clinical research on prevention and treatment of hyperlipidemia with Chinese patent medicines. Chinese Journal of Evidence-Based Medicine, 2024, 24(9): 1061-1069. doi: 10.7507/1672-2531.202310005 Copy

1.	Yang L, Li Z, Song Y, et al. Study on urine metabolic profiling and pathogenesis of hyperlipidemia. Clin Chim Acta, 2019, 495: 365-373.
2.	Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis, 2020, 19(1): 23.
3.	中國心血管健康與疾病報告2022概要. 中國循環雜志, 2023, 38(6): 583-612.
4.	Bu?dak ?, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol, 2019, 70(6): 511-519.
5.	中國心血管病一級預防指南. 實用心腦肺血管病雜志, 2021, 29(1): 44, 64.
6.	Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease' risk factors. Curr Cardiol Rev, 2018, 14(3): 153-163.
7.	中國血脂管理指南修訂聯合專家委員會. 中國血脂管理指南(2023年). 中國循環雜志, 2023, 38(3): 237-271.
8.	曾雨虹, 劉靜, 劉軍, 等. 超高危ASCVD患者的界定標準對住院ACS患者降脂治療需求的影響. 中華心血管病雜志, 2020, 48(12): 1039-1046.
9.	Gong Y, Li X, Ma X, et al. Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study Ⅱ. Clin Cardiol, 2021, 44(11): 1575-1585.
10.	Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2019, 140(11): e596-e646.
11.	魏停, 潘曉峰, 鄢子欣, 等. 中醫藥治療高脂血癥研究概況. 實用中醫內科雜志, 2022, 36(7): 137-139.
12.	崔小數, 曹珊, 陳芳, 等. 高脂血癥的中醫研究概述. 中國中醫藥現代遠程教育, 2020, 18(3): 139-142.
13.	馬貴萍, 章怡祎. 高脂血癥的中醫藥治療研究進展. 中西醫結合心腦血管病雜志, 2019, 17(14): 2116-2119.
14.	陳靜, 谷志彬. 中成藥在高脂血癥治療中的合理應用. 內蒙古中醫藥, 2012, 31(21): 70-71.
15.	田金徽, 李倫, 張俊華. 證據圖撰寫注意事項. 中國藥物評價, 2019, 36(2): 81-85.
16.	Schmucker C, Motschall E, Antes G, et al. Methods of evidence mapping. a systematic review. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013, 56(10): 1390-1397.
17.	李沐陽, 張福利, 蔡潤津, 等. 證據圖研究現狀分析. 中國藥物評價, 2019, 36(3): 161-164.
18.	中國中西醫結合學會心血管病專業委員會動脈粥樣硬化與血脂異常專業組. 血脂異常中西醫結合診療專家共識. 中國全科醫學, 2017, 20(3): 262-269.
19.	中國居民營養與慢性病狀況報告(2020年). 營養學報, 2020, 42(6): 521.
20.	Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016, 248: 2-9.
21.	Ding W, Cheng H, Yan Y, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing, China. J Epidemiol, 2016, 26(12): 637-645.
22.	木熱地里·賽米. 心腦血管共患疾病血脂分布特點及危險因素分析. 烏魯木齊: 新疆醫科大學, 2022.
23.	Li X, Liu B, Duan N, et al. Clinical efficacy and safety of Chinese patent medicine combined with oseltamivir for the treatment of adult influenza: a systematic review and meta-Analysis. Am J Chin Med, 2022, 50(4): 1043-1061.
24.	Miake-Lye IM, Mak S, Lee J, et al. Massage for ain: an evidence map. J Altern Complement Med, 2019, 25(5): 475-502.
25.	李倫, 楊克虎, 田金徽, 等. 一種新的證據總結方法—證據圖簡介. 中國循證兒科雜志, 2011, 6(3): 230-232.
26.	韓如雪, 劉澳林, 陳賢坤, 等. 血脂康治療高脂血癥系統評價的再評價. 中藥新藥與臨床藥理, 2019, 30(1): 110-116.
27.	廣東省藥學會. 醫療機構超藥品說明書用藥管理專家共識. 中國現代應用藥學, 2017, 34(3): 436-438.
28.	劉珺, 王瑱, 孔令越, 等. 復方丹參滴丸聯合辛伐他汀片治療高脂血癥40例臨床觀察. 河北中醫, 2015, (1): 93-94,158.
29.	石翠娥. 通心絡治療高脂血癥的療效觀察. 實用心腦肺血管病雜志, 2011, 19(4): 599-599.
30.	任燕萍, 蘆小燕, 周菲, 等. 700例藥品不良反應報告超說明書用藥情況分析. 中國現代應用藥學, 2016, 33(11): 1474-1477.
31.	趙鳴芳. 辨病辨證并治與辨證論治的比較研究. 南京中醫藥大學學報, 2022, 38(8): 655-665.
32.	管慧. 中醫藥臨床療效評價的替代指標構建及應用—以慢性心力衰竭為例. 濟南: 山東中醫藥大學, 2022.
33.	王新陸, 朱明軍, 王建茹, 等. 基于病證結合的中醫經典名方上市后評價要點. 中國中藥雜志, 2021, 46(8): 2004-2009.
34.	Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a) and cardiovascular disease in Chinese population: a Beijing Heart Society expert scientific statement. JACC Asia, 2022, 2(6): 653-665.
35.	程紅, 肖培, 侯冬青, 等. 2017年北京市6-16歲兒童青少年血脂異常流行特征及相關因素. 中國循環雜志, 2020, 35(6): 566-572.
36.	He H, Pan L, Du J, et al. Prevalence of, and biochemical and anthropometric risk factors for, dyslipidemia in children and adolescents aged 7 to 18 years in China: a cross-sectional study. Am J Hum Biol, 2019, 31(5): e23286.
37.	汪翼. 小兒血脂異常的臨床診療. 中國臨床醫生, 2013, 41(5): 5-7.
38.	向偉. 兒童青少年脂質異常血癥早期預防與成人期心血管健康. 中國兒童保健雜志, 2023, 31(7): 697-702.
39.	Siri-Tarino PW, Krauss RM. Diet, lipids, and cardiovascular disease. Curr Opin Lipidol, 2016, 27(4): 323-328.
40.	張培珍. 血脂異常的中老年人調脂運動處方的研究. 北京: 北京體育大學, 2004.
41.	周潔, 向紅丁, 陳偉, 等. 胰島素抵抗和血脂異常的關系. 中國糖尿病雜志, 2010, 18(10): 740-741.
42.	王富軍, 王文琦. 《中國2型糖尿病防治指南(2020年版)》解讀. 河北醫科大學學報, 2021, 24(12): 1365-1371.
43.	周嘉強. 糖尿病患者的血脂管理. 浙江醫學, 2021, 43(21): 2275-2278, 2288.

1. Yang L, Li Z, Song Y, et al. Study on urine metabolic profiling and pathogenesis of hyperlipidemia. Clin Chim Acta, 2019, 495: 365-373.
2. Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis, 2020, 19(1): 23.
3. 中國心血管健康與疾病報告2022概要. 中國循環雜志, 2023, 38(6): 583-612.
4. Bu?dak ?, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol, 2019, 70(6): 511-519.
5. 中國心血管病一級預防指南. 實用心腦肺血管病雜志, 2021, 29(1): 44, 64.
6. Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease' risk factors. Curr Cardiol Rev, 2018, 14(3): 153-163.
7. 中國血脂管理指南修訂聯合專家委員會. 中國血脂管理指南(2023年). 中國循環雜志, 2023, 38(3): 237-271.
8. 曾雨虹, 劉靜, 劉軍, 等. 超高危ASCVD患者的界定標準對住院ACS患者降脂治療需求的影響. 中華心血管病雜志, 2020, 48(12): 1039-1046.
9. Gong Y, Li X, Ma X, et al. Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study Ⅱ. Clin Cardiol, 2021, 44(11): 1575-1585.
10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2019, 140(11): e596-e646.
11. 魏停, 潘曉峰, 鄢子欣, 等. 中醫藥治療高脂血癥研究概況. 實用中醫內科雜志, 2022, 36(7): 137-139.
12. 崔小數, 曹珊, 陳芳, 等. 高脂血癥的中醫研究概述. 中國中醫藥現代遠程教育, 2020, 18(3): 139-142.
13. 馬貴萍, 章怡祎. 高脂血癥的中醫藥治療研究進展. 中西醫結合心腦血管病雜志, 2019, 17(14): 2116-2119.
14. 陳靜, 谷志彬. 中成藥在高脂血癥治療中的合理應用. 內蒙古中醫藥, 2012, 31(21): 70-71.
15. 田金徽, 李倫, 張俊華. 證據圖撰寫注意事項. 中國藥物評價, 2019, 36(2): 81-85.
16. Schmucker C, Motschall E, Antes G, et al. Methods of evidence mapping. a systematic review. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2013, 56(10): 1390-1397.
17. 李沐陽, 張福利, 蔡潤津, 等. 證據圖研究現狀分析. 中國藥物評價, 2019, 36(3): 161-164.
18. 中國中西醫結合學會心血管病專業委員會動脈粥樣硬化與血脂異常專業組. 血脂異常中西醫結合診療專家共識. 中國全科醫學, 2017, 20(3): 262-269.
19. 中國居民營養與慢性病狀況報告(2020年). 營養學報, 2020, 42(6): 521.
20. Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016, 248: 2-9.
21. Ding W, Cheng H, Yan Y, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing, China. J Epidemiol, 2016, 26(12): 637-645.
22. 木熱地里·賽米. 心腦血管共患疾病血脂分布特點及危險因素分析. 烏魯木齊: 新疆醫科大學, 2022.
23. Li X, Liu B, Duan N, et al. Clinical efficacy and safety of Chinese patent medicine combined with oseltamivir for the treatment of adult influenza: a systematic review and meta-Analysis. Am J Chin Med, 2022, 50(4): 1043-1061.
24. Miake-Lye IM, Mak S, Lee J, et al. Massage for ain: an evidence map. J Altern Complement Med, 2019, 25(5): 475-502.
25. 李倫, 楊克虎, 田金徽, 等. 一種新的證據總結方法—證據圖簡介. 中國循證兒科雜志, 2011, 6(3): 230-232.
26. 韓如雪, 劉澳林, 陳賢坤, 等. 血脂康治療高脂血癥系統評價的再評價. 中藥新藥與臨床藥理, 2019, 30(1): 110-116.
27. 廣東省藥學會. 醫療機構超藥品說明書用藥管理專家共識. 中國現代應用藥學, 2017, 34(3): 436-438.
28. 劉珺, 王瑱, 孔令越, 等. 復方丹參滴丸聯合辛伐他汀片治療高脂血癥40例臨床觀察. 河北中醫, 2015, (1): 93-94,158.
29. 石翠娥. 通心絡治療高脂血癥的療效觀察. 實用心腦肺血管病雜志, 2011, 19(4): 599-599.
30. 任燕萍, 蘆小燕, 周菲, 等. 700例藥品不良反應報告超說明書用藥情況分析. 中國現代應用藥學, 2016, 33(11): 1474-1477.
31. 趙鳴芳. 辨病辨證并治與辨證論治的比較研究. 南京中醫藥大學學報, 2022, 38(8): 655-665.
32. 管慧. 中醫藥臨床療效評價的替代指標構建及應用—以慢性心力衰竭為例. 濟南: 山東中醫藥大學, 2022.
33. 王新陸, 朱明軍, 王建茹, 等. 基于病證結合的中醫經典名方上市后評價要點. 中國中藥雜志, 2021, 46(8): 2004-2009.
34. Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a) and cardiovascular disease in Chinese population: a Beijing Heart Society expert scientific statement. JACC Asia, 2022, 2(6): 653-665.
35. 程紅, 肖培, 侯冬青, 等. 2017年北京市6-16歲兒童青少年血脂異常流行特征及相關因素. 中國循環雜志, 2020, 35(6): 566-572.
36. He H, Pan L, Du J, et al. Prevalence of, and biochemical and anthropometric risk factors for, dyslipidemia in children and adolescents aged 7 to 18 years in China: a cross-sectional study. Am J Hum Biol, 2019, 31(5): e23286.
37. 汪翼. 小兒血脂異常的臨床診療. 中國臨床醫生, 2013, 41(5): 5-7.
38. 向偉. 兒童青少年脂質異常血癥早期預防與成人期心血管健康. 中國兒童保健雜志, 2023, 31(7): 697-702.
39. Siri-Tarino PW, Krauss RM. Diet, lipids, and cardiovascular disease. Curr Opin Lipidol, 2016, 27(4): 323-328.
40. 張培珍. 血脂異常的中老年人調脂運動處方的研究. 北京: 北京體育大學, 2004.
41. 周潔, 向紅丁, 陳偉, 等. 胰島素抵抗和血脂異常的關系. 中國糖尿病雜志, 2010, 18(10): 740-741.
42. 王富軍, 王文琦. 《中國2型糖尿病防治指南(2020年版)》解讀. 河北醫科大學學報, 2021, 24(12): 1365-1371.
43. 周嘉強. 糖尿病患者的血脂管理. 浙江醫學, 2021, 43(21): 2275-2278, 2288.

Chinese Journal of Evidence-Based Medicine

Evidence mapping of clinical research on prevention and treatment of hyperlipidemia with Chinese patent medicines

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content